(Q80726123)
Statements
Phase 1 study of lumiliximab with detailed pharmacokinetic and pharmacodynamic measurements in patients with relapsed or refractory chronic lymphocytic leukemia (English)
John C Byrd
Susan O'Brien
Thomas J Kipps
Mark Weiss
Kanti Rai
Thomas S Lin
James Woodworth
Dee Wynne
Jennifer Reid
Arturo Molina
Bryan Leigh